研究单位：[1]Chinese Academy of Medical Sciences[2]Hebei Medical University Fourth Hospital[3]Tianjin Medical University Cancer Institute and Hospital[4]Anyang Tumor Hospital[5]The First Affiliated Hospital with Nanjing Medical University[6]Affiliated Hospital of Hebei University[7]Fujian Cancer Hospital[8]Tengzhou Central People's Hospital[9]The First Affiliated Hospital of Zhengzhou University[10]The Affiliated Hospital of Inner Mongolia Medical University[11]Sichuan Cancer Hospital and Research Institute[12]Department of Radiation Oncology, Cancer Hospital, National Cancer Center, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC),Beijing,China,100021
研究目的：
Ratiotherapy alone is the current standard treatment for elderly esophageal or esophagogastric cancer in China. And Little is known about chemoradiotherapy (CRT) in elderly patients. This study aimed to assess the efficiency and safety of simultaneous integrated boost (SIB) intensity modulated radiation therapy (IMRT) with S1 based SIB-IMRT followed by adjuvant chemotherapy with S1 in in elderly (age ≥70 years) esophageal or esophagogastric cancer patients
